Statin Initiation Cuts Mortality in Older Adults With Chronic Kidney Disease
By Lori Solomon HealthDay Reporter
FRIDAY, Jan. 5, 2024 -- Statin initiation may lower the risk for mortality and major adverse cardiovascular events (MACE) in older adults with chronic kidney disease (CKD) and no prior atherosclerotic cardiovascular disease (ASCVD), according to a study published online Dec. 6 in JAMA Network Open.
Odeya Barayev, M.D., from Ben Gurion University of the Negev in Be'er Sheva, Israel, and colleagues evaluated whether new statin use was associated with a lower risk for mortality or MACE among adults older than 65 years with CKD stages 3 to 4 and no history of ASCVD. The analysis included data from 14,828 U.S. veterans.
The researchers found that risk for all-cause mortality was lower among participants initiating statins versus noninitiators (hazard ratio, 0.91; 95 percent confidence interval, 0.85 to 0.97). There was a trend observed toward a lower risk for MACE (hazard ratio, 0.96; 95 percent confidence interval, 0.91 to 1.02). Results persisted in prespecified subgroup analyses.
"Among U.S. veterans older than 65 years with CKD stages 3 to 4 and no prior ASCVD, statin initiation was associated with a lower risk of all-cause mortality compared with no statin initiation. Results should be confirmed in a randomized clinical trial," the authors write. "However, until such trials are completed, these data argue against withholding or deprescribing statins for primary prevention in older patients with CKD stages 3 to 4."
Several authors disclosed financial ties to Novartis; one author disclosed ties to Anthos Therapeutics.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
Risk for Kidney Complications Increased After Heart Failure Hospitalization
WEDNESDAY, June 5, 2024 -- Older adults with heart failure have considerable risk for kidney complications, with 6 percent progressing to dialysis at one year after...
Plozasiran Reduces Triglyceride Levels in Mixed Hyperlipidemia
MONDAY, June 3, 2024 -- For individuals with mixed hyperlipidemia, plozasiran reduces triglyceride levels at 24 weeks, according to a study published online May 28 in the New...
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.